WJPMR, 2026, 12(4), 219-222. **Research Article** **Impact Factor: 7.555**

WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.wjpmr.com

ISSN (O): 2455-3301
ISSN (P): 3051-2557
Coden USA: WJPMBB

DYSLIPIDEMIA AND MEDOROGA: AN INTEGRATIVE RESEARCH PERSPECTIVE

Dr. Saba Tyagi*[1], Dr. Rajnikant Rohila[2], Dr. Harsha Singh[3]

[1]Post Graduate Scholar, [2]Professor and H.O.D, [3]Assistant Professor,
P.G Department of Kayachikitsa
Quadra Institute of Ayurveda, Roorkee, Uttarakhand.

***Corresponding Author: Dr. Saba Tyagi**

Post Graduate Scholar, P.G Department of Kayachikitsa Quadra Institute of Ayurveda, Roorkee, Uttarakhand.

DOI: https://doi.org/10.5281/zenodo.19415809

How to cite this Article: Dr. Saba Tyagi*[1], Dr. Rajnikant Rohila[2], Dr. Harsha Singh[3] (2026). Dyslipidemia and Medoroga: An Integrative Research Perspective, 12(4), 219–222.

Article Received on 05/03/2026 **Article Revised on 25/03/2026** **Article Published on 01/04/2026**

ABSTRACT

Dyslipidemia, characterized by abnormal concentrations of lipids in the bloodstream, is a major risk factor for atherosclerotic cardiovascular disease. Ayurveda describes a related metabolic disorder, Medoroga, arising from derangement of Meda Dhatu (fat tissue) and classified among Santarpanajanya Vyadhi (diseases of overnutrition). Both conditions share similarities in etiology, pathophysiology, clinical features, and long-term health consequences. This review explores their integrative relationship to provide a framework for early identification, prevention, and management of lipid disorders.

KEYWORDS: Dyslipidemia, Medoroga, Lipid Metabolism, Meda Dhatu, Santarpanajanya Vyadhi.

1. INTRODUCTION

Dyslipidemia, a clinical condition characterized by abnormal lipid concentrations in the bloodstream, is a major risk factor for atherosclerotic cardiovascular disease. Ayurveda describes a closely related metabolic disorder known as **Medoroga**, which arises from derangement of *Meda Dhatu* (fat tissue) and is classified among *Santarpanajanya Vyadhi* (diseases of overnutrition). Although described in different medical paradigms, both conditions share striking similarities in etiology, pathophysiology, clinical manifestations, and long-term health consequences. Understanding their relationship offers a comprehensive, integrative framework for early identification and management of lipid disorders. In modern physiology, lipids such as cholesterol and triglycerides are absorbed in the intestine and transported through the bloodstream via lipoproteins for energy production, hormone synthesis, and bile acid formation. The principal lipids relevant to dyslipidemia include LDL cholesterol, HDL cholesterol, triglycerides, and total cholesterol.

Ayurveda conceptualizes fat metabolism through the formation and nourishment of *Meda Dhatu*, governed by *Agni* (digestive and metabolic fire) and influenced primarily by *Kapha dosha*. Proper balance between nutrient intake, digestive capacity, and tissue metabolism maintains healthy *Meda Dhatu*; disturbances give rise to disorders such as Medoroga.

2. Etiological Correlation

2.1 Modern Medicine Perspective

- **Primary dyslipidemia:** Genetic mutations affecting lipid synthesis or clearance.
- **Secondary dyslipidemia:** Lifestyle factors, metabolic disorders, endocrine abnormalities, or medications.

2.2 Ayurvedic Perspective

Causative factors for Medoroga parallel modern mechanisms

- Excessive intake of fatty, sweet, oily, and heavy foods (*Guru, Snigdha, Madhura Ahara*).
- Sedentary lifestyle (*Avyayama*).
- Over-sleeping (*Ati Nidra*).
- Genetic susceptibility (*Beeja Dosha*).
- Psychological triggers, including stress-induced overeating.

Both systems recognize lifestyle-induced metabolic derangements as major contributors to lipid abnormalities.

3. Pathophysiology

3.1 Modern Perspective

1. **Increased Hepatic VLDL Production**
   - Excess free fatty acids from adipose tissue.
   - High carbohydrate/alcohol intake.
   - Insulin resistance.

2. **Impaired LDL Clearance**
   - Genetic mutations (e.g., familial hypercholesterolemia)
   - Insulin resistance and receptor downregulation.
   - High saturated fat intake.

3. **HDL Dysfunction**
   - Reduced reverse cholesterol transport due to obesity, inflammation, hypertriglyceridemia.

4. **Endothelial Dysfunction and Atherogenesis**
   - Oxidized LDL promotes endothelial injury, foam cell formation, and plaque development.

5. **Role of Insulin Resistance**
   - Increased lipolysis, decreased triglyceride clearance, and hepatic lipogenesis.

6. **Hormonal and Metabolic Influences**
   - Hypothyroidism, nephrotic syndrome, and diabetes exacerbate lipid abnormalities.

3.2 Ayurvedic Perspective

1. Kapha Dosha Prakopa

- Excessive Kapha leads to increased heaviness (*Guru*) and unctuousness (*Snigdha*), promoting fat accumulation.

2. Mandagni (Weak Digestive Fire)

- Impaired digestion → formation of *Aama* (metabolic toxins) → abnormal Meda Dhatu formation.

3. Aama Formation and Srotorodha

- Sticky, heavy Aama obstructs channels (*Srotas*), paralleling impaired lipid clearance and endothelial dysfunction.

4. Abnormal Meda Dhatu Metabolism

- Overproduction and accumulation of fat in abdomen (*Udara*), hips (*Sphik*), and breasts (*Stana*), mirroring central obesity.

5. Vicious Cycle: Meda-Vriddhi

- Accumulated Meda weakens its metabolic capacity (*Meda Dhatvagni Mandya*), causing further lipid accumulation.

6. Systemic Manifestations

- Excessive sweating, breathlessness, lethargy, and increased appetite correspond to modern findings of metabolic syndrome and hormonal imbalance.

3.3 Integrative Interpretation

Modern Medicine	Ayurveda	Integrated Interpretation
Insulin resistance	Mandagni	Impaired metabolic capacity
High LDL, triglycerides	Meda Vriddhi	Excess/abnormal fat accumulation
Oxidized LDL, inflammation	Aama	Toxic metabolic by-products
Atherosclerosis	Srotorodha	Channel obstruction
Obesity & metabolic syndrome	Sthaulya, Medoroga	Overnutrition disorder
Low HDL	Dhatu Kshaya	Loss of protective mechanisms

4. Clinical Features

4.1 Dyslipidemia

1. **Asymptomatic Presentation**
   - Most patients remain symptom-free; detected during routine blood tests.

2. **Cutaneous and Physical Signs (Severe/Genetic Cases)**
   - Xanthomas (tendon, tuberous, eruptive).
   - Xanthelasma palpebrarum.
   - Corneal arcus in younger individuals.

3. **Severe Hypertriglyceridemia**
   - Risk of acute pancreatitis, lipemic serum, nausea, and abdominal pain.

- **Cardiovascular Manifestations (Late Complications)**
- Coronary artery disease, cerebrovascular disease, peripheral artery disease.

4. **Metabolic Syndrome–Related Features**
   - Central obesity, insulin resistance, hypertension, NAFLD, acanthosis nigricans.

4.2 Medoroga (Ayurvedic Features)

General Physical Symptoms

Sthaulya: obesity, increased fat deposition.
Anga-Gaurava: heaviness of body.
Ati-Sweda: excessive sweating.
Dourgandhya: foul body odor.

1. Respiratory and Cardiovascular Symptoms

Shwasa-Krichrata: shortness of breath.
Vyayama Asahishnuta: exercise intolerance.

Digestive and Metabolic Symptoms

Kshudra Shwasa: mild breathlessness.
Kshut-Pipasa Adhikya: abnormal appetite and thirst.
Alasya: laziness.
Mandagni: weak digestive fire.

Psychological Manifestations
- Low mood, lethargy, emotional eating.

2. Secondary Complications
- *Prameha*: type 2 diabetes/metabolic syndrome.
- *Hridroga*: cardiovascular disorders.
- *Yakrit vriddhi*: fatty liver.
- Joint issues due to excess weight.

5. Diagnosis

5.1 Dyslipidemia

1. Lipid Profile Testing
- Fasting or non-fasting panel: total cholesterol, LDL-C, HDL-C, triglycerides, VLDL.

2. Recommended Cut-Off Values

Parameter	Optimal Level
LDL-C	<100 mg/dL (<70 mg/dL for high-risk)
HDL-C	>40 mg/dL (men), >50 mg/dL (women)
Triglycerides	<150 mg/dL
Total Cholesterol	<200 mg/dL
Non-HDL-C	<130 mg/dL

3. Risk Assessment Tools
- ASCVD Risk Calculator, Framingham Risk Score, SCORE.

4. Physical Examination
- Xanthomas, xanthelasma, corneal arcus, BMI, waist circumference, blood pressure.

5. Evaluation for Secondary Causes
- Thyroid, liver, kidney function, blood glucose, HbA1c.

6. Genetic Testing
- Considered for familial hypercholesterolemia or early-onset dyslipidemia.

5.2 Medoroga (Ayurvedic Diagnosis)

1. Nidana Panchaka-Based Assessment
- *Nidana*: causative factors.
- *Purvarupa*: premonitory signs.
- *Rupa*: clinical manifestations.
- *Samprapti*: pathogenesis.
- *Upashaya/Anupashaya*: factors that improve or worsen condition.

2. Darshana (Observation)
- Body habitus, skin changes, central obesity.

3. Sparshana (Palpation)
- Fat deposition, heaviness, pulse assessment.

4. Prashna (Interrogation)
- Appetite, thirst, sleep, diet, lifestyle, family history.

5. Agni and Aama Evaluation

Mandagni, toxic metabolite accumulation, impaired Dhatu formation.

Srotas Assessment

Meda Vaha Srotas obstruction, microvascular dysfunction, systemic involvement.

Management of Dyslipidemia

Dyslipidemia is a significant risk factor for cardiovascular disease. Management focuses on **reducing cardiovascular risk** through a combination of **lifestyle modifications** and **pharmacotherapy**.

1. Lifestyle Modifications

Lifestyle interventions are the cornerstone of dyslipidemia management and should be implemented in all patients:

Diet: Emphasize a diet low in saturated and trans fats, enriched with soluble fiber and omega-3 fatty acids.

Exercise: Engage in at least 150 minutes per week of moderate-intensity aerobic activity.

Weight Control: Achieve and maintain a healthy body mass index (BMI).

Smoking Cessation: Avoid tobacco in all forms.
Alcohol Moderation: Limit alcohol intake to recommended levels.

2. Pharmacological Therapy

The choice of drug therapy depends on the **type of lipid abnormality**, **cardiovascular risk**, and **presence of comorbidities**.

a) Statins (HMG-CoA Reductase Inhibitors)
Mechanism: Inhibit HMG-CoA reductase → reduce cholesterol synthesis → increase LDL receptor expression → lower LDL-C.
Examples: Atorvastatin, Rosuvastatin, Simvastatin

Indications: First-line therapy for high LDL-C; secondary prevention of coronary artery disease (CAD).

Adverse Effects: Myopathy, elevated liver enzymes, rare rhabdomyolysis.

b) Ezetimibe
Mechanism: Inhibits intestinal cholesterol absorption → reduces LDL-C.
Example: Ezetimibe 10 mg daily
Indications: Often combined with statins in high-risk patients.

c) PCSK9 Inhibitors
Mechanism: Monoclonal antibodies prevent LDL receptor degradation → markedly lower LDL-C.
Examples: Evolocumab, Alirocumab

- **Indications:** Familial hypercholesterolemia or statin-intolerant high-risk patients.
- **Note:** Injectable therapy; higher cost.

d) Fibrates
- **Mechanism:** Activate PPAR-α → increase lipoprotein lipase activity → lower triglycerides, modestly raise HDL-C.
- **Examples:** Fenofibrate, Gemfibrozil
- **Indications:** Hypertriglyceridemia >500 mg/dL to prevent pancreatitis.
- **Adverse Effects:** Gastrointestinal upset, myopathy (especially with statins), elevated liver enzymes.

e) Niacin (Vitamin B3)
- **Mechanism:** Inhibits hepatic VLDL synthesis → lowers LDL and triglycerides, raises HDL.
- **Indications:** Rarely used today due to side effects.
- **Adverse Effects:** Flushing, hyperglycemia, hepatotoxicity.

f) Omega-3 Fatty Acids
- **Mechanism:** Reduce hepatic VLDL synthesis → lower triglycerides.
- **Examples:** Icosapent ethyl
- **Indications:** Adjunct therapy in severe hypertriglyceridemia.

Ayurvedic Approach

Ayurvedic management emphasizes

1. Shodhana (Purificatory Therapies)
- *Vamana* (therapeutic emesis)
- *Virechana* (purgation)
- *Udwartana* (dry powder massage)

These therapies aim to reduce *Kapha* and correct *Meda Dhatu* metabolism.

2. Shamana (Palliative Therapies)
- *Medohara* herbs such as Guggulu, Triphala, Punarnava, Musta
- Metabolism-enhancing formulations targeting *Agni* and *Aama*

3. Ahara and Vihara (Diet and Lifestyle)
- Low-fat, Kapha-reducing diet
- Whole grains, barley, legumes, leafy vegetables
- Regular exercise, yoga, pranayama
- Regulation of sleep and stress.

6. CONCLUSION

Dyslipidemia and Medoroga represent parallel concepts in modern medicine and Ayurveda, respectively, highlighting the metabolic consequences of lipid imbalance and overnutrition. Both conditions share common etiological factors, pathophysiological mechanisms, and clinical manifestations, including obesity, insulin resistance, cardiovascular risk, and systemic complications. Integrative understanding allows for a holistic approach that combines **modern pharmacotherapy**—such as statins, fibrates, ezetimibe, and PCSK9 inhibitors—with **Ayurvedic interventions**, including Shodhana (purificatory therapies), Shamana (palliative treatments), and lifestyle modifications. Early detection, patient-specific interventions, and a synergy of conventional and traditional strategies can improve lipid profiles, reduce cardiovascular risk, and promote overall metabolic health. This integrative perspective encourages further research into combining evidence-based Ayurveda with contemporary lipid management to optimize patient outcomes.

REFERENCES

1. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. *Circulation*. 2019; 139: e1082–e1143.
2. National Cholesterol Education Program (NCEP) Expert Panel. Third Report of the NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *Circulation*. 2002; 106: 3143–3421.
3. Tyagi, R. & Mishra, S. Conceptual Understanding of Medoroga vis-à-vis Obesity and Metabolic Syndrome: An Ayurvedic Perspective. *Anc. Sci., Life*. 2015; 35(2): 80–88.
4. Sharma PV. *Charaka Samhita*, Vol. 1–3. Varanasi: Chaukhambha Orientalia; 2010.
5. Dash B. *Textbook of Ayurveda: Volume 2 – Kayachikitsa*. New Delhi: Concept Publishing Company; 2001.
6. Bays HE. Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating "sick fat cells" may decrease cardiovascular events. *Am J. Cardiol*., 2009; 104: 4E–9E.
7. Ston NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. *Circulation*. 2014; 129: S1–S45.
8. Ghosh, A. & Bhattacharya, S. Medoroga and Dyslipidemia: Integrative Perspectives on Lipid Metabolism Disorders. *J Ayurveda Integr Med*. 2020; 11(3): 312–321.